Bioniche Life Sciences Inc. Receives Canadian Regulatory Approval for Equine Anti-Inflammatory Product
October 27 2011 - 4:00PM
PR Newswire (Canada)
-NexHA(TM )to be available for sale in coming months- BELLEVILLE,
ON, Oct. 27, 2011 /CNW/ - Bioniche Life Sciences Inc. , a
research-based, technology-driven Canadian biopharmaceutical
company, today announced that it has received a notice of
compliance from Health Canada's Veterinary Drugs Directorate for a
low molecular weight hyaluronate sodium product for horses that the
Company expects to launch in the next several months. The new
product, NexHA(TM), is a specialized formulation of purified
hyaluronate sodium that can be administered to horses by
intravenous or intra-articular injection. It is indicated in the
treatment of joint dysfunction of the carpus or fetlock in horses
due to non-infectious synovitis associated with equine
osteoarthritis. Hyaluronate sodium acts as a replacement for
synovial fluid, the naturally occurring lubricant in articular
joints. Joint degeneration is associated with the loss of synovial
fluid, and the lack of its lubricant effects results in
considerable pain and inflammation for the horse. The Company has
been selling different formulations of sodium hyaluronate in Canada
(I.A. only), Australia and New Zealand - as Enhance(®)( )- since
2001/02. Both Enhance(®) and NexHA(TM) are produced with a sodium
hyaluronate solution that is obtained from a selective fermentation
source using a manufacturing process that is free from thermal
degrading effects. "Enhance® has been a very successful product for
us in Australia, and we look forward to making this new formulation
- NexHA(TM) - available to our Canadian equine veterinary
customers, followed by veterinarians in other global jurisdictions
in the future," said Mr. Andrew Grant, President of Bioniche Animal
Health (global). "Whether it's racing, sport or pleasure riding,
Bioniche has a broad range of equine products to support the
wellness and performance of all horses. Our portfolio includes
specialized nutritional supplements, joint care, wound care,
immunostimulants and products to assist through the reproduction
cycle from pregnancy to a healthy foal." About Bioniche Life
Sciences Inc. Bioniche Life Sciences Inc. is a research-based,
technology-driven Canadian biopharmaceutical company focused on the
discovery, development, manufacturing, and marketing of proprietary
and innovative products for human and animal health markets
worldwide. The fully-integrated company employs more than 200
skilled personnel and has three operating divisions: Human Health,
Animal Health, and Food Safety. The Company's primary goal is to
develop and commercialize products that advance human or animal
health and increase shareholder value. Bioniche Animal Health
develops, manufactures and markets veterinary biopharmaceutical
products worldwide. In North America, it has development,
manufacturing and marketing facilities in Belleville, Ontario,
Canada, Athens, Georgia, U.S.A. and Pullman, Washington, U.S.A. In
Australia, business is conducted from two sites: Sydney, New South
Wales, where sales and marketing, customer support and technical
service are located; and Armidale, New South Wales, where research,
development and manufacturing facilities are located. Bioniche Life
Sciences Inc. has been named one of the Top 50 Best Small and
Medium-Sized Employers in Canada for 2010. For more information,
please visit www.Bioniche.com. Except for historical information,
this news release may contain forward-looking statements that
reflect the Company's current expectation regarding future events.
These forward-looking statements involve risk and uncertainties,
which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly
and annual reporting. Bioniche Life Sciences Inc. CONTACT: Jennifer
Shea, Vice-President, Communications, Investor
&GovernmentRelationsBioniche Life Sciences Inc.Telephone: (613)
966-8058; from Australia: 0011 1 613-966-8058Cell: (613) 391-2097;
from Australia: 0011 1 613-391-2097Jennifer.Shea@Bioniche.com
Copyright
Purpose Canadian Financi... (TSX:BNC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Purpose Canadian Financi... (TSX:BNC)
Historical Stock Chart
From Jul 2023 to Jul 2024